Development of a human model for tauopathies
Company 2016
Janssen Pharmaceutica N.V., Beerse, Belgium
Tau aggregation is a pathological process present in several neurodegenerative diseases and has become increasingly interesting as an alternative therapeutic target in Alzheimer's disease. Nevertheless, human models are scarce and there is a need to develop new methodologies that allow scalable assays to reproduce key features of tauopathies in a human context. In this study, transduced human iPSC were used to generate human cortical neurons in 3D conditions to develop a model that can reproduce tau aggregation. Moreover, AlphaLISA technology was used to detect aggregated tau in a high-throughput screening format. The results show that the developed set-up produces reproducible results with different cell lines and among different uses, proving that this can be a powerful tool to investigate potential therapeutic strategies for tauopathies.
Development of a scalable, high-throughput-compatible assay to detect tau aggregates using iPSC-derived cortical neurons maintained in a three-dimensional culture format
Alfredo Cabrera-Socorro
Added on: 08-19-2021
[1] https://journals.sagepub.com/doi/10.1177/1087057116638029[2] https://data.jrc.ec.europa.eu/dataset/a8fd26ef-b113-47ab-92ba-fd2be449c7eb
